Gilead’s Antiviral Drug “Remdesivir” receives Emergency Use Authorization (EUA) letter from USFDA for the treatment of COVID-19
Gilead’s Antiviral Drug “Remdesivir” receives Emergency Use Authorization (EUA) letter from USFDA for the treatment of COVID-19 Gilead’s Antiviral Drug “Remdesivir” receives Emergency Use Authorization (EUA) letter from USFDA for the treatment of COVID-19. Remdesivir is a nucleoside ribonucleic acid (RNA) polymerase inhibitor. Remdesivir shall be administered through parenteral route (Product is available in the form of preservative-free lyophilized solid that is to be reconstituted with sterile water for injection and diluted into saline prior to intravenous (IV) administration). Remdesivir is a direct acting antiviral drug that inhibits viral RNA synthesis. It is an investigational drug and is not currently approved for any indication. Remdesivir has activity in cell culture and animal models against SARS-CoV, MERS-CoV, and SARS-CoV-2. In the letter issued to Gilead on 1 st May 2020,